Despite the considerable therapeutic benefits of targeting the PD-1/PD-L1 axis, including robust efficacy in numerous cancers and relatively low toxicity compared to other immunotherapies 94,95-only 20-30% of patients respond to PD-1/PD-L1 monotherapy. This evidence concerns the gene PDCD1 and cancer.